ZBH
60
-2
CMCSA
48
2
MTCH
37
7
IP
70
2
CVX
46
5
CAH
47
3
DOV
61
-2
HRB
51
2
ORLY
53
-3
NOV
58
3
EIX
77
2
FLS
73
-2
CF
59
3
HRL
39
15
BBY
40
3
DVN
16
3
EXR
57
-2
ROK
55
8
DNB
78
6
PNW
66
3
ZBH
60
-2
CMCSA
48
2
MTCH
37
7
IP
70
2
CVX
46
5
CAH
47
3
DOV
61
-2
HRB
51
2
ORLY
53
-3
NOV
58
3
EIX
77
2
FLS
73
-2
CF
59
3
HRL
39
15
BBY
40
3
DVN
16
3
EXR
57
-2
ROK
55
8
DNB
78
6
PNW
66
3
Financhill
Back

NanoVibronix 10K Form

Buy
59

NAOV
NanoVibronix

Last Price:
0.65
Seasonality Move:
10.99%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NAOV News And Ratings

See the #1 stock for the next 7 days that we like better than NAOV

NAOV Financial Statistics

Sales & Book Value

Annual Sales: $2.28M
Cash Flow: $-836K
Price / Cash Flow: 0
Annual Sales: $0.67
Price / Book: 1.36

Profitability

EPS (TTM): -1.23000
Net Income (TTM): $-3.09M
Gross Margin: $1.54M
Return on Equity: -91.36%
Return on Assets: -50.36%

NanoVibronix Earnings Forecast

Key NanoVibronix Financial Ratios

  • The Gross Profit Margin over the past 13 years for NAOV is 67.32%.
  • The Selling, General & Administrative Expenses for NAOV have been equal to 209.72% of Gross Profit Margin.
  • The Research & Development expenses have been 8.10% of Revenue.
  • The Interest Expense is -3.64% of Operating Income.
  • The Net Earning history of NAOV is -162.55% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 7 years.

NanoVibronix Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: NAOV
CUSIP: 63008J
Website: nanovibronix.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.74
Quick Ratio: 0.84

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NAOV Technical Analysis vs Fundamental Analysis

Buy
59
NanoVibronix (NAOV) is a Buy

Is NanoVibronix a Buy or a Sell?

  • NanoVibronix stock is rated a Buy
    The current NanoVibronix [NAOV] share price is $0.61. The Score for NAOV is 59, which is 18% above its historic median score of 50, and infers lower risk than normal.